vs
EXACT SCIENCES CORP（EXAS）与ITT INC.（ITT）财务数据对比。点击上方公司名可切换其他公司
ITT INC.的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.1B vs $878.4M），ITT INC.净利率更高（12.5% vs -9.8%，领先22.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs 13.5%），ITT INC.自由现金流更多（$187.4M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.6%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
ITT Inc是一家总部位于美国康涅狄格州斯坦福德的制造企业，前身为ITT集团，主要面向航空航天、交通、能源及工业领域供应特种零部件，旗下设有工业流程、运动技术、连接与控制技术三大业务板块。
EXAS vs ITT — 直观对比
营收规模更大
ITT
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出9.7%
13.5%
净利率更高
ITT
高出22.3%
-9.8%
自由现金流更多
ITT
多$67.0M
$120.4M
两年增速更快
EXAS
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $131.7M |
| 毛利率 | 70.1% | 35.5% |
| 营业利润率 | -9.4% | 17.0% |
| 净利率 | -9.8% | 12.5% |
| 营收同比 | 23.1% | 13.5% |
| 净利润同比 | 90.1% | 3.7% |
| 每股收益（稀释后） | $-0.45 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASITT
| Q4 25 | $878.4M | $1.1B | ||
| Q3 25 | $850.7M | $999.1M | ||
| Q2 25 | $811.1M | $972.4M | ||
| Q1 25 | $706.8M | $913.0M | ||
| Q4 24 | $713.4M | $929.0M | ||
| Q3 24 | $708.7M | $885.2M | ||
| Q2 24 | $699.3M | $905.9M | ||
| Q1 24 | $637.5M | $910.6M |
净利润EXASITT
| Q4 25 | $-86.0M | $131.7M | ||
| Q3 25 | $-19.6M | $126.9M | ||
| Q2 25 | $-1.2M | $121.0M | ||
| Q1 25 | $-101.2M | $108.4M | ||
| Q4 24 | $-864.6M | $127.0M | ||
| Q3 24 | $-38.2M | $161.1M | ||
| Q2 24 | $-15.8M | $119.2M | ||
| Q1 24 | $-110.2M | $111.0M |
毛利率EXASITT
| Q4 25 | 70.1% | 35.5% | ||
| Q3 25 | 68.6% | 35.6% | ||
| Q2 25 | 69.3% | 35.7% | ||
| Q1 25 | 70.8% | 34.6% | ||
| Q4 24 | 69.0% | 34.1% | ||
| Q3 24 | 69.4% | 35.5% | ||
| Q2 24 | 69.8% | 34.9% | ||
| Q1 24 | 70.0% | 33.0% |
营业利润率EXASITT
| Q4 25 | -9.4% | 17.0% | ||
| Q3 25 | -3.0% | 18.0% | ||
| Q2 25 | -0.3% | 18.0% | ||
| Q1 25 | -13.6% | 16.5% | ||
| Q4 24 | -122.8% | 17.2% | ||
| Q3 24 | -5.6% | 23.5% | ||
| Q2 24 | -3.8% | 17.6% | ||
| Q1 24 | -16.7% | 16.4% |
净利率EXASITT
| Q4 25 | -9.8% | 12.5% | ||
| Q3 25 | -2.3% | 12.7% | ||
| Q2 25 | -0.1% | 12.4% | ||
| Q1 25 | -14.3% | 11.9% | ||
| Q4 24 | -121.2% | 13.7% | ||
| Q3 24 | -5.4% | 18.2% | ||
| Q2 24 | -2.3% | 13.2% | ||
| Q1 24 | -17.3% | 12.2% |
每股收益（稀释后）EXASITT
| Q4 25 | $-0.45 | $1.64 | ||
| Q3 25 | $-0.10 | $1.62 | ||
| Q2 25 | $-0.01 | $1.52 | ||
| Q1 25 | $-0.54 | $1.33 | ||
| Q4 24 | $-4.69 | $1.54 | ||
| Q3 24 | $-0.21 | $1.96 | ||
| Q2 24 | $-0.09 | $1.45 | ||
| Q1 24 | $-0.60 | $1.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.7B |
| 总债务越低越好 | — | $521.5M |
| 股东权益账面价值 | $2.4B | $4.1B |
| 总资产 | $5.9B | $6.3B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EXASITT
| Q4 25 | $964.7M | $1.7B | ||
| Q3 25 | $1.0B | $516.4M | ||
| Q2 25 | $858.4M | $467.9M | ||
| Q1 25 | $786.2M | $439.8M | ||
| Q4 24 | $1.0B | $439.3M | ||
| Q3 24 | $1.0B | $460.9M | ||
| Q2 24 | $946.8M | $425.5M | ||
| Q1 24 | $652.1M | $423.0M |
总债务EXASITT
| Q4 25 | — | $521.5M | ||
| Q3 25 | — | $577.7M | ||
| Q2 25 | — | $622.5M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $232.6M | ||
| Q3 24 | — | $467.8M | ||
| Q2 24 | — | $190.0M | ||
| Q1 24 | — | $230.5M |
股东权益EXASITT
| Q4 25 | $2.4B | $4.1B | ||
| Q3 25 | $2.5B | $2.7B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.4B | $2.8B | ||
| Q4 24 | $2.4B | $2.8B | ||
| Q3 24 | $3.2B | $2.7B | ||
| Q2 24 | $3.2B | $2.6B | ||
| Q1 24 | $3.1B | $2.6B |
总资产EXASITT
| Q4 25 | $5.9B | $6.3B | ||
| Q3 25 | $5.9B | $5.1B | ||
| Q2 25 | $5.8B | $5.0B | ||
| Q1 25 | $5.7B | $4.8B | ||
| Q4 24 | $5.9B | $4.7B | ||
| Q3 24 | $6.7B | $4.9B | ||
| Q2 24 | $6.7B | $4.4B | ||
| Q1 24 | $6.4B | $4.4B |
负债/权益比EXASITT
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.08× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | — | 0.09× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $227.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $187.4M |
| 自由现金流率自由现金流/营收 | 13.7% | 17.8% |
| 资本支出强度资本支出/营收 | 3.6% | 3.8% |
| 现金转化率经营现金流/净利润 | — | 1.73× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $547.5M |
8季度趋势，按日历期对齐
经营现金流EXASITT
| Q4 25 | $151.7M | $227.8M | ||
| Q3 25 | $219.9M | $173.9M | ||
| Q2 25 | $89.0M | $153.7M | ||
| Q1 25 | $30.8M | $113.4M | ||
| Q4 24 | $47.1M | $223.2M | ||
| Q3 24 | $138.7M | $123.9M | ||
| Q2 24 | $107.1M | $157.7M | ||
| Q1 24 | $-82.3M | $57.8M |
自由现金流EXASITT
| Q4 25 | $120.4M | $187.4M | ||
| Q3 25 | $190.0M | $146.2M | ||
| Q2 25 | $46.7M | $137.3M | ||
| Q1 25 | $-365.0K | $76.6M | ||
| Q4 24 | $10.7M | $186.8M | ||
| Q3 24 | $112.6M | $87.3M | ||
| Q2 24 | $71.2M | $134.5M | ||
| Q1 24 | $-120.0M | $30.1M |
自由现金流率EXASITT
| Q4 25 | 13.7% | 17.8% | ||
| Q3 25 | 22.3% | 14.6% | ||
| Q2 25 | 5.8% | 14.1% | ||
| Q1 25 | -0.1% | 8.4% | ||
| Q4 24 | 1.5% | 20.1% | ||
| Q3 24 | 15.9% | 9.9% | ||
| Q2 24 | 10.2% | 14.8% | ||
| Q1 24 | -18.8% | 3.3% |
资本支出强度EXASITT
| Q4 25 | 3.6% | 3.8% | ||
| Q3 25 | 3.5% | 2.8% | ||
| Q2 25 | 5.2% | 1.7% | ||
| Q1 25 | 4.4% | 4.0% | ||
| Q4 24 | 5.1% | 3.9% | ||
| Q3 24 | 3.7% | 4.1% | ||
| Q2 24 | 5.1% | 2.6% | ||
| Q1 24 | 5.9% | 3.0% |
现金转化率EXASITT
| Q4 25 | — | 1.73× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | 1.76× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 0.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
ITT
| Industrial Process | $423.1M | 40% |
| Motion Technologies | $360.8M | 34% |
| Connect Control Technologies | $271.2M | 26% |
